This hawkish legal strategy indicates that a new phase of the GLP-1 gold rush has begun—a crackdown against any entity selling non-name-brand medications. Tirzepatide, the active ingredient in ...

Only 1 in 5 Large Companies' Health Plans Cover New Weight-Loss Meds for Employees By Robin Foster HealthDay Reporter WEDNESDAY, Oct. 9, 2024 (HealthDay News) -- When it comes to coverage for the ...

Mercey Livingston is a health and wellness writer and certified Integrative Nutrition Health Coach. She's written about fitness and wellness for Well+Good, Women's Health, Business Insider, and ...

2 Non-stimulant ADHD medications of different classifications work in different ways. Both Alpha-2 adrenergic agonists and SNRIs affect norepinephrine (or noradrenaline) levels in the nervous ...

One of the most prominent medical developments in recent years has been the emergence of a class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1 RAs). The best known of these ...

We are now in the era of weight-loss drugs. Decisions on how these drugs will be used look likely to shape our future health and even what our society might look like. And, as researchers are ...

Skin pigmentation may act as a 'sponge' for some medications, potentially influencing the speed with which active drugs reach their intended targets, a pair of scientists report. Skin pigmentation ...

Dementia treatment is more than just medication. It can include lifestyle changes, multimodal therapy, and environmental management, as well. Your dementia treatment plan will depend on underlying ...

Oct 9 (Reuters) - The U.S. Centers for Medicare & Medicaid Services released on Wednesday a preliminary list of 101 generic drugs that would be available for no more than $2 for a month's supply ...

Out-of-pocket costs for drugs for neurologic diseases such as MS, Parkinson's and Alzheimer's disease are climbing sharply, according to research led by Amanda Gusovsky, of Ohio State University ...

But so far, no microRNA-based drugs have been approved by the US Food and Drug Administration, an agency that many countries look to for guidance. The field has hit “a little bit of a slump ...